# Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.

> **NCT01120093** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 79 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Aclidinium bromide 100 μg bid
- **DRUG:** Aclidinium bromide 200 μg bid
- **DRUG:** Aclidininum bromide 400 μg bid
- **DRUG:** Placebo
- **DRUG:** Formoterol 12 μg bid

## Key facts

- **NCT ID:** NCT01120093
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01120093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01120093, "Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01120093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*